Molecular Characterization of Multiple Myeloma Ethnic Disparity

多发性骨髓瘤种族差异的分子特征

• 批准号: 9137629
• 负责人: Carl Ola Landgren
• 金额: $ 10.6万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-10 至 2018-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9137629
• 关键词: Molecular; Characterization; Multiple; Myeloma; Ethnic; Molecular; Characterization; Multiple; Myeloma; Ethnic

ABSTRACT Despite that multiple myeloma (MM) in Blacks clearly has a biologically different natural history, clinically, Blacks are assessed using the same genetic approaches as the whole population. The proposed project will afford us the opportunity to identify and characterize MM in the Black population with much higher genetic and molecular resolution. It will answer questions such as whether Blacks have, in general, better survival because of the presence of more low risk genetic aberrations and whether these changes alter the effect of treatment drug. Our conclusions may have immense regulatory impact. For example, certain MM therapies may be indicated sooner in the treatment course in Blacks. Alternatively, some therapies may be found to have minimal efficacy and indication in Blacks with certain molecular subtypes. This proposal will be the first study to characterize the molecular subtypes of MM in Blacks in a systematic fashion, investigate the effect of these on novel therapy outcomes, and potentially have major impact on regulatory approvals of future therapies. Therefore, it is imperative to focus on this under-represented population and at least begin to understand the differences in MM pathophysiology, which may ultimately lead to improved outcomes.

抽象的 尽管黑人的多发性骨髓瘤（MM）显然具有生物学上不同的自然史，但 在临床上，黑人使用与整个人群相同的遗传方法评估。 拟议的项目将使我们有机会识别和表征黑色的MM 人口具有更高的遗传和分子分辨率。它将回答诸如 一般而言，黑人是否拥有更低的风险，是否有更好的生存 遗传像差以及这些变化是否改变了治疗药物的作用。我们的 结论可能会产生巨大的监管影响。例如，某些MM疗法可能是 在黑人治疗课程中提前指示。另外，可能会发现某些疗法 具有某些分子亚型的黑人的功效和指示最小。这个建议 将是第一个表征黑人中MM分子亚型的研究 时尚，研究这些对新疗法结果的影响，并有可能具有重大 对未来疗法的监管批准的影响。因此，必须专注于此 代表性不足的人口，至少开始了解MM的差异 病理生理学，最终可能导致改善的结果。